Wnt-C59 (C59)

Catalog No.S7037 Batch:S703703

Print

Technical Data

Formula

C25H21N3O
Molecular Weight 379.45 CAS No. 1243243-89-1
Solubility (25°C)* In vitro DMSO 76 mg/mL (200.28 mM)
Ethanol 5 mg/mL (13.17 mM)
Water Insoluble
In vivo (Add solvents to the product individually and in order)
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Wnt-C59 (C59) is a PORCN inhibitor for Wnt3A-mediated activation of a multimerized TCF-binding site driving luciferase with IC50 of 74 pM in HEK293 cells.
Targets
Porcn [1]
(HEK293 cells )
74 pM
In vitro Wnt-C59 (C59) is claimed to inhibit PORCN enzyme activity at nanomolar concentrations. At 10 nM, it blocks the palmitoylation-dependent Wnt–WLS interaction in HeLa cells transfected with either WNT3A-V5 or WNT8A-V5 plasmids. This compound (100 nM) prevents incorporation of palmitate into WNT3A in HeLa cells transfected with WNT3A-V5, consistent with inhibition of PORCN activity. It (100 nM) inhibits the activity of all splice variants of murine PORCN in PORCN-null HT1080 cells transfected with PORCN. Wnt-C59 is a nanomolar inhibitor of mammalian PORCN acyltransferase activity and blocks activation of all evaluated human Wnts. It does not significantly inhibit the proliferation of any of 46 tested cancer cell lines in vitro at concentrations that completely inhibit PORCN. Wnt-C59 is capable to significantly inhibit proliferation and comparable to the ICG-001 treated NMuMG (NMG) cells. It inhibits sphere formation by threefold in NMuMG (NMG) cells, which is dependent on Wnt10b-secretion. This compound inhibits proliferation of human MDA-MB 231 cells by >50%. As a Porcupine inhibitor, it blocks radiolabel incorporation of [125I]iodo-pentadecanoate in mouse L-Wnt3a cells transfected with Flag-Porcupine.
In vivo Wnt-C59 (C59) concentration remains greater than 10-fold above the in vitro IC50 for at least 16 hours following a single oral dose (5 mg/kg) in mice. At 10 mg/kg, it prevents growth of MMTV-WNT1 tumors in female nude mice orthotopically transplanted with independent MMTV-WNT1 tumors. This compound also decreases Wnt pathway activity and proliferation in such tumors, as evident by reduced expression of β-catenin target genes. When topically administered at 10% for 4 weeks, it reduces the size of dysplasia in SmoM2-expressing cells in adult K14CREER/Rosa–SmoM2 mice.

Protocol (from reference)

Cell Assay:

[2]
  • Cell lines

    NMuMG (NMG) and MDA-MB 231 cells

  • Concentrations

    --

  • Incubation Time

    48 hours

  • Method

    Seed cells at a concentration of 4×103/well in 100 μL culture medium containing various amounts of Wnt-C59 (C59). Incubate cells for 48 hours at 37 ℃. Add 10 μL/well cell proliferation reagent and incubate for 4 hours at 37 ℃. Shake thoroughly for 1 min on a shaker. Measure the absorbance of the samples in a microplate (ELISA) reader.
Animal Study:

[1]
  • Animal Models

    Female nude mice orthotopically transplanted with independent MMTV-WNT1 tumors

  • Dosages

    10 mg/kg

  • Administration

    orally

References

  • https://pubmed.ncbi.nlm.nih.gov/23188502/
  • https://pubmed.ncbi.nlm.nih.gov/23307470/
  • https://pubmed.ncbi.nlm.nih.gov/23416332/
  • https://pubmed.ncbi.nlm.nih.gov/23178882/

Customer Product Validation

<p>Application of XAV939 or Wnt-c59 with FGF2 blocks the accumulation of nuclear b-catenin in MGPCs, and increases levels of p38MAPK in Muller glia, whereas levels of cFos are unaffected. a, b, Eyes were injected with four consecutive daily injections of FGF2 6 XAV939 or Wnt-c59, BrdU 24 h after the last injection of FGF2, and retinas harvested 24 h later. Wnt-c59 (treated). a, b-catenin in the nuclei of Sox91 Muller glia/MGPCs on 70% grayscale background.</p>

, , Dev Neurobiol, 2016, 76(9):983-1002.

In vitro treatment with C59 (Wnt-i) decreased the active (non-phosphorylated) β-catenin level in Eed cKO primary rib chondrocytes. Chondrocytes were cultured for 24 h in the presence of C59 (Wnt-i).

Data from [ , , Nat Commun, 2016, 7:12047 ]

Migration of L428 cells (b) and KM-H2 (c) after 72 h pretreatment with 5 μm Wnt-C59 or DMSO with (+CM) or without (−CM) the simultaneous stimulation with the respective cHL-CM for 24 h (mean±s.d., n=3, one-way ANOVA and Dunn’s post hoc test). Note the inhibition of migration by porcupine inhibitors, which is rescued by CM. (d) Invasion of L428 or KM-H2 cells after 72 h pretreatment with 5 μm Wnt-C59 or DMSO (mean±s.d., n=3 two-way ANOVA and Bonferroni’s post hoctest). (e) Adhesion of DMSO- or Wnt-C59-pretreated L428 cells on either HUVECs (white) or collagen I (gray) (mean±s.d., n=5, 2-way ANOVA and Bonferroni’s post hoc test). Note the decrease of adhesion after WNT inhibition (*P<0.05 and ***P<0.001).

Data from [ , , Oncogene, 2017, 36(1):13-23 ]

(A) Body weight changes over the study by treatment group (LGK low: LGK974 at 3 mg/kg/day; LGK high: LGK974 at 6 mg/kg/kg/day; C59: Wnt-C59). (B) Femur length at necropsy. (C) Total body bone mineral density (BMD) at necropsy. (D) Spine BMD at necropsy.

Data from [ , , J Endocrinol, 2018, 238(1):13-23 ]

Selleck's Wnt-C59 (C59) Has Been Cited by 181 Publications

MYC ecDNA promotes intratumour heterogeneity and plasticity in PDAC [ Nature, 2025, 10.1038/s41586-025-08721-9] PubMed: 40074906
IGFBP2 Mediates Human iPSC-Cardiomyocyte Proliferation in a Cellular Contact-Dependent Manner [ Circ Res, 2025, 137(10):1279-1291] PubMed: 41031396
Suspended Tissue Open Microfluidic Patterning (STOMP) [ Adv Sci (Weinh), 2025, 12(25):e2501148] PubMed: 40298902
Stage-specific cardiotoxicity induced by bisphenol A using human pluripotent stem cell-derived 2D- and 3D-cardiomyocyte models [ J Tissue Eng, 2025, 16:20417314251383006] PubMed: 41163723
Binding of LncDACH1 to dystrophin impairs the membrane trafficking of Nav1.5 protein and increases ventricular arrhythmia susceptibility [ Elife, 2025, 12RP89690] PubMed: 39773412
Generation and characterization of induced pluripotent stem cells of small apes [ Front Cell Dev Biol, 2025, 13:1536947] PubMed: 40177132
Cardioprotection by poloxamer 188 is mediated through increased endothelial nitric oxide production [ Sci Rep, 2025, 15(1):15170] PubMed: 40307302
Dual-cardiotoxicity evaluation of torsadogenic risk drugs using human iPSC-derived cardiomyocytes [ Biochem Biophys Res Commun, 2025, 786:152756] PubMed: 41043280
Differentiation, Maintenance, and Contraction Profiling of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes [ Bio Protoc, 2025, 15(5):e5222] PubMed: 40084084
Image-based, pooled phenotyping reveals multidimensional, disease-specific variant effects [ bioRxiv, 2025, 2025.07.03.663081] PubMed: 40631108

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.